PimedBio Selected for Johnson & Johnson Innovation’s Global Network, JLABS

— Accelerating Global Clinical Trials and Commercialization of PMB212 through Strategic Access to Global Innovation Hubs —

PimedBio is pleased to announce its selection as a resident company of JLABS, the premier global life science incubator network managed by Johnson & Johnson Innovation.

JLABS is a world-renowned innovation platform dedicated to identifying and nurturing high-potential biotech startups. Selection for JLABS involves a highly competitive and rigorous vetting process, ensuring that only companies with proven technological excellence and marketability are chosen. This achievement serves as international validation of the innovation and global commercialization potential of PimedBio’s pipeline, led by its cancer stemness inhibitor, PMB212.

• Access to Global Networks: PimedBio will gain access to JLABS’ world-class facilities and resources across the globe, along with exclusive mentoring opportunities from Johnson & Johnson’s extensive pool of scientific and business experts.

• Acceleration of Clinical Trials and Commercialization: The partnership is expected to provide significant momentum for establishing global clinical strategies for PMB212, which is entering U.S. FDA Phase 1 trials, while expanding partnering opportunities for global licensing-out (L/O).

• Investment and Strategic Partnerships: PimedBio plans to accelerate strategic alliances and investment activities by leveraging the JLABS network to engage with global investors and leading pharmaceutical companies.

•  

 "This selection for JLABS is a major milestone, proving that our differentiated drug discovery platform and pipeline meet the highest global standards," said Noh Sung-gu, CEO of PimedBio. "With the professional support and mentorship from J&J, we will accelerate the development of our innovative therapeutics and solidify our position as a leading global biopharmaceutical company."

PimedBio remains committed to driving innovation and delivering sustainable value to our stakeholders within the global healthcare ecosystem.